PEAK1

Across TCGA pan-cancer cohorts, PEAK1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PEAK1 data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PEAK1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PEAK1 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

PDAC, LSCC, and HNSC are the cancer types where PEAK1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	II,III,IV	0.593	0.955	.002	20	view →
LSCC	DFS	Median	II,III,IV	0.836	1.000	.005	14	view →
HNSC	DFS	Quartile	II,III,IV	0.972	0.855	.009	10	view →
CCRCC	OS	Median	All	1.000	0.680	.016	6	view →
GBM	OS	Median	All	0.641	0.429	.028	6	view →
LUAD	DFS	Tertile	II,III,IV	0.721	0.991	.028	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PEAK1–PDAC (DFS)

Open the PDAC breakdown →